ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer. AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the DESTINY-Breast03 trial, as well as several other indications, including HR ...

The United States is facing a COVID-19 surge this summer as the more contagious delta variant spreads. More than 655,000 Americans have died from COVID-19 while over 4.6 million people have died ...

See the latest Daiichi Sankyo Co Ltd stock price (4568:XTKS), related news, valuation, dividends and more to help you make your investing decisions.